EXELIOM

exeliom-logo

Exeliom is a clinical-stage biopharmaceutical company tackling the use of commensal bacteria as drugs. Their mission is to harness the therapeutic potential of gut microbiota to enable people to lead longer and healthier lives. They are committed to developing the next generation of probiotics: innovative microbial therapies. Exeliom develops a new class of medicines called Live Biotherapeutics based on their growing understanding of the central role of the microbiota in the immune system. The company was founded in 2016 and is headquartered in Dijon, France.

#SimilarOrganizations #People #Financial #Website #More

EXELIOM

Social Links:

Industry:
Biopharma Biotechnology Health Care Pharmaceutical

Founded:
2016-01-01

Address:
Dijon, Bourgogne, France

Country:
France

Website Url:
http://www.nextbiotix.com

Total Employee:
1+

Status:
Active

Email Addresses:
[email protected]

Total Funding:
7 M EUR

Technology used in webpage:
Google Apps For Business Microsoft Azure DNS Wix Wix DNS


Similar Organizations

aimmune-therapeutics-logo

Aimmune Therapeutics

Aimmune Therapeutics is a clinical-stage biopharmaceutical company that improves the lives of people with food allergies.

edgewise-therapeutics-logo

Edgewise Therapeutics

Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization.

piqur-therapeutics-logo

PIQUR Therapeutics

PIQUR Therapeutics is a Swiss pharmaceutical company focusing on the discovery and development of anti-cancer drugs.


Current Advisors List

harry-sokol_image

Harry Sokol Clinical Advisor & Co-Founder @ Exeliom
Advisor

philippe-langella_image

Philippe Langella Preclinical Advisor & Co-Founder @ Exeliom
Advisor

patrick-gervais_image

Patrick Gervais Co-founder& Manufacturing Advisor @ Exeliom
Advisor

Current Employees Featured

benjamin-hadida_image

Benjamin Hadida
Benjamin Hadida CEO & Co-Founder @ Exeliom
CEO & Co-Founder
2016-12-01

Founder


benjamin-hadida_image

Benjamin Hadida

harry-sokol_image

Harry Sokol

patrick-gervais_image

Patrick Gervais

philippe-langella_image

Philippe Langella

Investors List

inra-2_image

INRA

INRA investment in Series A - Exeliom

sofimac-innovation_image

Sofimac Innovation

Sofimac Innovation investment in Series A - Exeliom

cap-innovest_image

Cap Innov'Est

Cap Innov'Est investment in Series A - Exeliom

biocodex_image

Biocodex

Biocodex investment in Series A - Exeliom

auriga-partners_image

Auriga Partners

Auriga Partners investment in Series A - Exeliom

Official Site Inspections

http://www.nextbiotix.com

Unable to get host informations!!!

Loading ...

More informations about "Exeliom"

Exeliom - Crunchbase Company Profile & Funding

Exeliom is a clinical-stage biopharmaceutical company tackling the use of commensal bacteria as drugs. Their mission is to harness the therapeutic potential of gut microbiota to enable people …See details»

Nextbiotix becomes Exeliom Biosciences

Nextbiotix becomes Exeliom Biosciences. Back to news. #biotech #crohn'sdisease #clinicalstudy #milestones #immunotherapy #microbiome #livebiotherapeutics. Oct 19, 2023. Exeliom …See details»

Exeliom Biosciences - LinkedIn

Exeliom Biosciences is a clinical-stage biotechnology company developing next-generation immunotherapies in immuno-oncology and immuno-inflammation. Our novel candidates harness...See details»

Nextbiotix SAS - life-sciences-europe.com

Based in Dijon, with offices in Paris (France), NEXTBIOTIX is a biopharmaceutical company developing Live Biotherapeutics using commensal bacteria as drugs to treat major …See details»

exeliom

Exeliom Biosciences is a clinical-stage biotechnology company developing next-generation therapies in immuno-oncology and immuno-inflammation. in indications where dysregulated immunity hampers efficacy, including …See details»

Nextbiotix - VentureRadar

Nexbiome therapeutics is a private incubator of microbiome biotech companies. Our mission is to identify the best research projects and turn them into biotech companies that will bring …See details»

Exeliom Biosciences Announces Series A Extension and …

Jul 3, 2023 · Exeliom Biosciences (formerly Nextbiotix), a clinical-stage biopharmaceutical company leveraging its unique knowledge of the microbiome-immunomodulation axis to develop next-generation immunotherapies, …See details»

Exeliom Biosciences closes its Series A funding at €24 …

Jul 3, 2023 · Paris-based Exeliom Biosciences (formerly Nextbiotix), a clinical-stage biopharmaceutical company leveraging its unique knowledge of the microbiome-immunomodulation axis to develop next-generation …See details»

Nextbiotix - Biotech.info

“We are committed to developing a new generation of medicines: monoclonal microbial therapies. We will use our breakthrough translational approach, our unique relationships with our …See details»

Nextbiotics - Crunchbase Company Profile & Funding

Nextbiotics is a biotechnology platform that engineers viruses for good. Where is Nextbiotics's headquarters? Nextbiotics is located in San Francisco, California, United States. Who invested …See details»

Exeliom - Funding, Financials, Valuation & Investors - Crunchbase

Exeliom is a clinical-stage biopharmaceutical company tackling the use of commensal bacteria as drugs.See details»

Exeliom Biosciences - Craft

Exeliom Biosciences (formerly Nextbiotix) is a biotechnology company developing monoclonal microbial therapies. Its lead candidate, a mono-strain product, uses Faecalibacterium …See details»

News - exeliom

France-based Exeliom Biosciences (formerly Nextbiotix) is exploring these possibilities. The biotech is developing single microbial strains intended to safely act on immunomodulatory …See details»

€7m for French microbiome start-up - European Biotechnology …

Jul 6, 2018 · Microbiome start-up Nextbiotix raised € 7m in a Series A round. The Paris-based biotech uses commensal bacteria as drugs to treat major inflammatory bowel diseases. …See details»

Microbiome start-up Nextbiotix nets €7m to address

Jul 12, 2018 · French-based biotech start-up Nextbiotix has successfully raised €7m in a Series A financing round, to develop microbiome-based approaches that address inflammatory bowel …See details»

Nextbiotix's Lead IBD Therapy Candidate Receives €7M in Funding

Jul 23, 2018 · Nextbiotix has secured €7 million ($8.2 million) in funding to develop NBX1650, the company’s lead bacterial candidate for the treatment of inflammatory bowel disease (IBD). …See details»

Exeliom - Contacts, Employees, Board Members, Advisors & Alumni

Exeliom is a clinical-stage biopharmaceutical company tackling the use of commensal bacteria as drugs.See details»

Nextbiotix raises €7m in a Series A round to tackle inflammatory …

Jul 6, 2018 · PRESS RELEASE - Nextbiotix, a microbiome biotech company developing innovative Live Biotherapeutics using commensal bacteria as drugs to treat major …See details»

Nextbiotix réussit une première levée de 7 M€ pour s’attaquer aux ...

Jul 6, 2018 · COMMUNIQUE DE PRESSE - Nextbiotix, une nouvelle startup dans le domaine du microbiome, développe une approche mono-souche pour traiter les maladies inflammatoires …See details»

Microbiome startup Nextbiotix raises €7M to tackle inflammatory …

Jul 5, 2018 · Nextbiotix has raised €7 million ($8 million) to develop a bacterial treatment for inflammatory bowel diseases. The series A round will support work to rebalance the gut …See details»

linkstock.net © 2022. All rights reserved